Global Footprint MINAKEM operates across multiple European and North American sites, including Dunkirk, Beuvry-la-Forêt, Louvain-la-Neuve and Montreal, with regulatory approvals from FDA and local agencies. This multi-site footprint, combined with Minafin Group backing and access to additional networks, enables flexible supply, rapid tech transfer and scalable manufacturing for pharmaceutical partners.

HPAPI Prowess The company specializes in highly potent API manufacturing for innovators and generics, complemented by custom development and complex synthesis capabilities in areas such as chiral, steroid and multi-step chemistry, supported by advanced analytical and solid form laboratories. This positions MINAKEM as a partner for potent, difficult APIs and process optimization.

ADC Capabilities MINAKEM has pursued linker development for ADCs, leveraging HPAPI and specialized chemistry strengths to support programs from linker design through API production, creating opportunities with oncology biotech and pharma companies pursuing antibody–drug conjugates.

Regulatory Excellence All sites operate under FDA and local health authority approvals, with strong quality assurance, regulatory affairs, safety, health and environment functions, offering reliable compliance, quality and smoother tech transfers for customers with stringent regulatory requirements.

Sustainability Edge MINAKEM has earned sustainability recognition including an EcoVadis Gold Medal, signaling a commitment to ESG and responsible operations that can support sales conversations with customers prioritizing sustainable supply chains and green chemistry.